• NeoGenomics flagged eight new oncology research abstracts slated for presentation at the ASCO Annual Meeting in Chicago, May 29 to June 2, 2026.
• Planned updates center on molecular residual disease monitoring, liquid biopsy versus tissue profiling, and real-world evidence across solid tumors and blood cancers.
• One interim analysis from an MD Anderson collaboration is expected to outline how tumor-informed ctDNA tracking may support recurrence monitoring in colorectal cancer.
• Separate breast cancer work is set to assess whether earlier molecular relapse detection could help guide follow-up and intervention strategies.
• The program also previews development of a lower-sample AML MRD flow assay aimed at improving sensitivity and turnaround time, positioning the platform for hematology trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605260705BIZWIRE_USPR_____20260526_BW677942) on May 26, 2026, and is solely responsible for the information contained therein.